Your daily Tecan update from SLAS2016 in San Diego, Jan 23-27.
Not rendering correctly? View this email as a web page here.

Meet a Tecan Expert at SLAS2016

Dear Lab User,

What's new this year at SLAS2016? For one thing: Tecan will unveil the new Spark® 20M microplate reader with Te-Cool™ (read more below). 

You'll also be hearing from Tecan Experts in lab automation, next generation sequencing, liquid handling, automating genomic workflow and other "hot" topics in our daily SLAS2016 updates. We hope you enjoy reading about what's happening at this important event, whether you'll be attending or not. 


The Tecan SLAS2016 Team

 Meet us at SLAS2016 booth #831 and talk to one of our Experts:



Not subscribed?

Get this update in your inbox.


Spark 20M Te-Cool

Spark® 20M with Te-cool™

Keep cool. There’s a better life ahead for your bioassay.

Confident decisions in drug discovery builds on reliable results from bioassays. Maintaining a stable temperature is critical for consistency. Te-Cool™ now ensures that your live cell bioassays for enzymatic and kinetic studies are run to the highest standards. Tecan introduces the Spark® 20M microplate reader with Te-Cool. It’s the coolest idea for empowering your research and screening studies. Read more...


Spark-10M Tecan

Spark® 10M

Be confident in your data from automated live cell-based assays.

Now it’s easy to keep an eye on your cells with the new Spark 10M, which includes imaging for normalizing signals, monitoring cell quality, and triggering actions.  Read more…


Blog Cancer Resistance Part 1

Breaking the resistance to anticancer drugs

Part 1: How a failed contraceptive led to targeted therapy success

In 1996, Dr. Charles Sawyers at Memorial Sloan Kettering Cancer Center, USA, became involved in the initial testing of a drug for the treatment of chronic myeloid leukemia (CML). The drug, imatinib (later to be launched as Gleevec), could be taken once a day with few side effects and had a dramatic clinical result. Even patients in advanced stages of the disease, reliant on oxygen and with only a few weeks to live, became symptom-free almost immediately. The trouble was, those same patients quickly developed a resistance to the drug and suffered a relapse. 


Breaking the resistance to anticancer drugs

Breaking the resistance to anticancer drugs

Part II: Chasing a moving target

The so-called ‘War against Cancer’ started with US President Richard Nixon’s National Cancer Act of 1971. It turned out to be many battles on many fronts as cancer was confirmed to be not one but a myriad of diseases. Not only that, but each cancer cell in a given patient has a different genetic make-up. It can differ in its response to treatment and also its ability to develop resistance.

As Dr. Michael Gottesman, one of the pioneers in resistance research, put it in his review of 2002: “To paraphrase Tolstoy in the opening lines of Anna Karenina, normal cells are all alike in their response to drugs, but cancer cells each respond in their own way.”

Meet the Tecan Experts

Get a free evaluation of your lab workflow or book a time to meet a Tecan Expert at SLAS2016.

Read more about these Tecan Experts:

Simon Fogarty Tecan Expert Lab Automation
Simon Fogarty - Expert Lab Automation
Avinash_Peddi Tecan Expert
Avinash Peddi - Expert Robotics/Lab Automation
Kevin Moore Tecan Expert
Kevin Moore - Expert Drug Discovery, ADME
Mike Mueller Tecan Expert
Mike Mueller - Expert Genomic Workflows

Bronwen Forster Tecan Expert
Bronwen Forster - Expert Liquid Handling
Jon Smith Tecan Expert NGS automation
Jon Smith - Expert NGS Automation
David-Wold Tecan Experts SLAS2016 Components
David Wold - Expert Components
Michael_Fejtl Tecan Expert Cell Biology
Michael Fejtl - Expert Cell Biology & Detection


Share this:

  Follow Tecan FB TW G+ YT IN